D-Wave Quantum falls nearly 3% as earnings miss overshadows revenue beat
Eric A. Hughes, Executive Vice President, Global R&D and Chief Medical (TASE:BLWV) Officer at Teva Pharmaceutical (TADAWUL:2070) Industries LTD (NASDAQ:NYSE:TEVA), sold 52,742 ordinary shares on August 1, 2025. The shares were sold at a price of $15.1575, totaling $799,436.
The sales were executed at prices ranging from $15.13 to $15.31. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan adopted on November 15, 2024.
On the same day, Hughes also exercised options to acquire 52,742 ordinary shares.
In other recent news, Teva Pharmaceutical Industries reported second-quarter earnings that surpassed analyst expectations. This development aligns with the company’s ongoing "Pivot to Growth" strategy. While the company’s shares saw a rise in pre-market trading, the focus remains on its financial performance. Additionally, Teva’s CEO, Richard Francis, addressed potential U.S. tariffs, stating that the company is well-positioned to handle these despite uncertainties in the sector. He highlighted that 70% of Teva’s generics business operates outside the United States, which may mitigate the impact of any tariffs. Most of Teva’s branded drugs, including its largest drug Austedo for Huntington’s Disease, are manufactured within the U.S. These recent developments reflect Teva’s strategic positioning in the pharmaceutical industry.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.